Product
MEN1611
3 clinical trials
2 indications
Indication
Colorectal CancerIndication
Breast CancerClinical trial
Open-label, Multicentre, Phase Ib/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing RegimensStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based TherapyStatus: Active (not recruiting), Estimated PCD: 2023-12-21
Clinical trial
Phase II Study for PIK3CA/PTEN-altered Advanced Metaplastic Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinStatus: Recruiting, Estimated PCD: 2025-07-01